Generic Ultiva Availability
ULTIVA (remifentanil hydrochloride - injectable; injection)
Manufacturer: MYLAN INSTITUTIONAL
Approval date: July 12, 1996
Strength(s): EQ 1MG BASE/VIAL, EQ 2MG BASE/VIAL, EQ 5MG BASE/VIAL [RLD]
Has a generic version of Ultiva been approved?
No. There is currently no therapeutically equivalent version of Ultiva available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultiva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Stable formulations of remifentanil
Issued: February 2, 1999
Inventor(s): Gatlin; Larry Alan & Heiman; Shirley Ann & Lewis; Janet Sue
Assignee(s): Glaxo Wellcome Inc.
Stable formulations of 3-›4-methoxycarbonyl-4-›(1 -oxopropyl)phenylamino!-1-piperidine!propanoic acid, methyl ester, generally referred to as remifentanil, are disclosed. In particular, stabilized lyophilized solid composition are disclosed comprising certain acids, most preferably comprising glycine.Patent expiration dates:
- September 10, 2017✓
- March 10, 2018✓
- September 10, 2017
- Ultiva Consumer Information (Wolters Kluwer)
- Ultiva Consumer Information (Cerner Multum)
- Ultiva Advanced Consumer Information (Micromedex)
- Ultiva AHFS DI Monographs (ASHP)
- Remifentanil Consumer Information (Wolters Kluwer)
- Remifentanil Consumer Information (Cerner Multum)
- Remifentanil Intravenous Advanced Consumer Information (Micromedex)
- Remifentanil Hydrochloride AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|